Last reviewed · How we verify
Unfractionated heparin
At a glance
| Generic name | Unfractionated heparin |
|---|---|
| Also known as | heparin misc, heparin Ca, Calciparine, heparin beef lung, heparin Na |
| Sponsor | Chen Jing |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (PHASE4)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery (PHASE1)
- Impact of Ligament of Marshall Resection on Atrial Fibrillation Occurrence in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Controlled Trial (NA)
- Zeus (510K) - 24024 - Stability in Venous and Arterial Blood
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- Heparin for RAO Post-Transradial Angiography in AIS (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Unfractionated heparin CI brief — competitive landscape report
- Unfractionated heparin updates RSS · CI watch RSS
- Chen Jing portfolio CI